linjc16/ctgov huggingface dataset:
Early Detection of Pulmonary Arterial Hypertension Using Cardiac Magnetic Resonance Imaging

Study Overview
=================
Brief Summary
-----------------
Cardiac magnetic resonance imaging has emerged as a potential valuable test for the early detection of Pulmonary Arterial Hypertension. A number of reports have provided some preliminary evidence that Pulmonary Artery (PA) stiffness may be accurately detected by imaging of the pulmonary artery in order to measure PA stiffness. In addition, cardiac MRI could play provide early and effective treatment for Pulmonary Arterial Hypertension (PAH).

Official Title
-----------------
Early Detection of Pulmonary Arterial Hypertension Using Cardiac Magnetic Resonance Imaging

Conditions
-----------------
Pulmonary Hypertension, Pulmonary Arterial Hypertension

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Consecutive patients aged ≥ 18 years with PAH as dictated by a comprehensive examination and echocardiography will be included for enrollment. Exclusion Criteria: Age < 18 years Pregnancy Mechanical ventilation Acute or chronic renal failure (creatinine clearance < 30 ml/min or requiring renal replacement therapy) Inability to perform MRI (i.e. claustrophobia, severe obesity (> 150 kg), device incompatible with MRI) Significant arrhythmia that precludes adequate ECG-gating for the MRI (i.e. atrial fibrillation with highly variable cycle lengths) Prior heart or lung transplantation Left ventricular systolic (ejection fraction < 50%) or diastolic failure (based on Framingham criteria for heart failure with preserved ejection fraction) Significant left-sided valvular disease (≥ moderate aortic stenosis, mitral stenosis, aortic regurgitation, mitral regurgitation) or prior valve surgery

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 99 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
pulsatility, normal subjects, mild pulmonary hypertension, exercise-associated pulmonary hypertension
Reactivation of Inactive Blood Donors

Study Overview
=================
Brief Summary
-----------------
Blood donor retention is a critical strategy to ensure the safety and sufficiency of clinical blood supply. An effective strategy can prevent donors from lapsing and eventually becoming inactive.

Official Title
-----------------
Effective Methods for Reactivating Inactive Blood Donors: a Stratified Randomized Controlled Study

Conditions
-----------------
Blood Donor

Intervention / Treatment
-----------------
* Other: Telephone call
* Other: SMS


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Donated blood at least once between Januanry 1 to September 30 2016, and the blood test result is qualified. Exclusion Criteria: Having donated again before intervened.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Telephone group<br>The telephone group received telephone calls. All non-response and refusing donors were included for further follow-up. Donors who answered the phone call and agreed to be interviewed were asked the reasons why they had stopped donating according to a pre-designed questionnaire. All of the responsed donors were re-recruited by altruistic appeal. | Other: Telephone call<br>* From 20 October to 10 November 2016, telephone calls were given to the donors in the phone call group<br>|
| Experimental: SMS group<br>The SMS intervention group received the following text message:Dear donors, Thank you for your donation through which your love brought hope to those helpless patients and your donated blood reignited the fire in their lives. If you can, please consider donating blood again to save a life. Thank you again for your support! . All donors either receiving or not receiving the message were included for further follow-up. | Other: SMS<br>* Text messages were sent to an equal number of donors in the SMS group<br>|
| No Intervention: Control group<br>No intervention will be giving to this group. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Blood donation rate | Number of blood donors donate blood again divided by the number of participants in every group after intervened. | 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Self-deferral reasons of not donating | The reasons of not donating again in the telephone group. | 1 day |
Postpartum Pelvic Floor Rehabilitation and Information Provided by the Health Care Providers

Study Overview
=================
Brief Summary
-----------------
The aim of this work is to evaluate the experience of Postpartum Pelvic Floor Rehabilitation (PPFR) according to the information given by the health care providers. There is to improve medical practice and to give the right information in at the right time to the patient.

Detailed Description
-----------------
Postpartum Pelvic Floor Rehabilitation is an important central stage of the postpartum period. It allows, if it is well done, to reduce complications related to childbirth, (pelvic floor disorders: urinary, sexual or anal disorders ) and to increase quality of life of women in postpartum period. But, what about the woman's opinion and experience of PPFR? Previous studies have evaluated the effectiveness of PPFR but not the woman's experience. It is interesting to evaluate the experience of PPFR according to the information given by the health care providers. There is to improve medical practice and to give the right information in at the right time to the women

Official Title
-----------------
Opinion Survey on Postpartum Pelvic Floor Rehabilitation According to the Quality of Information Provided by the Health Care Providers

Conditions
-----------------
Recovery of Function

Intervention / Treatment
-----------------
* Other: Questionnaire


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All women undergoing postpartum pelvic floor rehabilitation at the Departmental Hospital Center of Vendee Exclusion Criteria: Refusal to participate in the study Patient did not complete all her PPFR sessions at the Departmental Hospital Center of Vendee Patient unable to understand the protocol, read the information note and answer the questionnaires Patient under tutelage, curatorship, mandate of future protection, family habilitation

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Questionnaire|Self-questionnaire reported before the first PPFR session and after the last session|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Overall experience of the PPFR according to information given by the health care providers | Self-evaluation of the overall experience of postpartum pelvic floor rehabilitation | through study completion, an average of 5 weeks |
The Impact of Patient Involvement in Decision-Making About Heart Disease Prevention

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine whether providing patients with information about their global coronary heart disease (CHD) risk and effective risk-reducing strategies allows them to make appropriate decisions about heart disease prevention.

Detailed Description
-----------------
Background: Low utilization of effective CHD prevention strategies may be due to many factors, but chief among them is the lack of patient involvement in prevention decisions. We undertook this study to test the effectiveness of an individually-tailored, computerized decision aid about CHD on patients' discussions with their doctor and their plans for CHD prevention. Methods: We conducted a pilot randomized trial in a convenience sample of adults with no previous history of cardiovascular disease to test the effectiveness of an individually-tailored, computerized decision aid about CHD prevention against a risk factor list that patients could present to their doctor.

Official Title
-----------------
Decision Aid to Improve Coronary Heart Disease Risk Modification: a Pilot Randomized Trial

Conditions
-----------------
Cardiovascular Disease

Intervention / Treatment
-----------------
* Device: Heart-to-Heart Decision Aid


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: presenting for routine medical care with regular medical provider able to understand, speak, and read English Exclusion Criteria: prior history of cardiovascular disease history of serious medical illness that would limit candidacy for screening previous participation in intensive risk modification as part of diabetes study in our clinic no cholesterol measurement in the last 3 years, limiting ability to provide up-to-date risk estimate

Ages Eligible for Study
-----------------
Minimum Age: 35 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Single


Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: Heart-to-Heart Decision Aid|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Discussion with provider about CHD risk reduction |  |  | 
| Stated plans for CHD risk reduction |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Knowledge about CHD prevention |  |  | 
| Perception of CHD risk |  |  | 
| Interest in participating in decision-making |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Risk Assessment, Decision Support Technique, Physician-Patient Relations, Prevention and Control
Prospective Analysis and Comparison of Stress Echo to Real-Time Myocardial Contrast Stress Echo

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to prospectively analyze and compare conventional stress echocardiograms and real-time myocardial contrast stress echocardiograms; and to determine the effect of contrast agents used during real-time myocardial contrast stress echocardiograms on serum troponin I levels.

Detailed Description
-----------------
To compare two different stress echocardiograms (conventional Stress echocardiograms or Real-time Myocardial Contrast Stress Echocardiograms) that are in routine clinical use. The information, including the digital images that are collected during the stress tests is used to determine if the usse of specialized imaging techniques and ultrasound contrast can better detect blockage in blood flow to the heart and predict how patients outcome may be affected by this detection of a blockage.

Official Title
-----------------
Prospective Analysis and Comparison of Conventional Stress Echocardiograms and Real-Time Myocardial Contrast Stress Echocardiogram; for Bristol-Myers Squibb Medical Imaging: The Definity RT-P During DSE Database

Conditions
-----------------
Evaluation of Troponin I Levels

Intervention / Treatment
-----------------
* Other: Dobutamine: Perflutren Lipid Microsphere


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male or female Age > 19 years Scheduled for a stress echocardiography Are conscious and coherent, and able to communicate effectively with trial personnel For troponin evaluation, only hospitalized patients who had a troponin level drawn in the morning of and prior to stress echocardiogram will be included. Exclusion Criteria: Pregnant and breast feeding women are excluded from participation because of the possibility of a bias as CSE is routinely used in pregnant patients secondary to lack of human studies to determine the fetal risk of use of Definity. Age < 19 years old Known or suspected hypersensitivity to ultrasound contrast agents or other drugs used for the study Possibility that potential subject may be pregnant Studies where RT-MCE was specifically requested by the ordering physician

Ages Eligible for Study
-----------------
Minimum Age: 19 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Dobutamine: Perflutren Lipid Microsphere|Dobutamine with starting dose of 10 micrograms/kg/min and increased gradually to a maximum dose of 50 micrograms/kg/min Definity will be infused continuously at a rate of 4mL/min|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Comparison of Oral Molecules Preventing Relapses in Multiple Sclerosis

Study Overview
=================
Brief Summary
-----------------
The aim of this observational study is to compare Dimethyl fumarate (DMF) and Teriflunomide on both clinical and MRI outcomes in patients with relapsing-remitting multiple sclerosis (RRMS) from French Observatory of Multiple Sclerosis (French MS cohort )

Official Title
-----------------
Comparison of Oral Molecules Preventing Relapses in Multiple Sclerosis

Conditions
-----------------
Relapsing-remitting Multiple Sclerosis

Intervention / Treatment
-----------------
* Other: Non interventional study


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: RRMS Patients with an EDSS score ranging between 0 and 5.5, who initiated either DMF or Teriflunomide before 1/01/2016 and with an available MRI scan and EDSS assessment respectively within 12 and 6 months before treatment initiation Patients who had consent to OFSEP registry Naive patient or treated with prior first line treatment : interferon, glatiramer acetate Exclusion Criteria: Patient with progressive multiple sclerosis Patients with prior second line Patient with no MRI or EDSS score within the year before DMF or Teriflunomide initiation.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Non interventional study|Not applicable - Non interventional Study|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Relapse within first year of treatment | Proportion of patients experimenting at least one relapse within the first year of treatment | 12 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Occurrence of clinical event at Two years | Proportion of patients with at least one relapse at two years of treatment | 24 months | 
| Progression of disability | Proportion of patients with a progression of disability defined by any increased of EDSS score compared to baseline | 12 months and 24 months | 
| Radiological disease activity | Proportion of patients with at least one Gd-enhancing lesion and the proportion of patients with at least one new T2-lesion on MRI scans compared to baseline MRI scan Probablity | 12 months and 24 months | 
| Adverse drug reaction | Number and description of adverse reaction. Proportion of patients who had stopped treatment due to AR | 12 months and 24 months |
Clinical Evaluation of the IONA Test for Non-invasive Pre Natal Screening in Twin Pregnancies

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate the performance of the IONA® test which is a non-invasive prenatal test (NIPT) for Down's syndrome and other chromosomal abnormalities in twin pregnancies, from a maternal blood sample.

Detailed Description
-----------------
350 low risk and 150 high risk women with twin pregnancies will be recruited to produce a large cohort evaluation the use of the IONA test in twin pregnancies for Downs, Edwards and Patau syndrome. Reserve samples will also be used to further develop the test for other chromosomal abnormalities.

Official Title
-----------------
Clinical Evaluation of the IONA Test for Non-invasive Pre Natal Screening in Twin Pregnancies

Conditions
-----------------
Down Syndrome, Patau Syndrome, Edward's Syndrome

Intervention / Treatment
-----------------
* Procedure: Blood sample


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Currently pregnant with twin foetuses at time of entry to study Have had or are about to have a conventional screening test (combined/quad test, ultrasound scan or other NIPT) If identified as high risk, intend to undergo prenatal invasive diagnosis and/or undergoing invasive prenatal therapy such as laser treatment for TTTS where a sample of amniotic fluid is taken for karyotyping. Exclusion Criteria: Participant herself has down syndrome or other chromosomal abnormality

Ages Eligible for Study
-----------------
Minimum Age: 16 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Screening
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Low Risk<br>350 Low risk The only intervention is a 20 ml blood sample will be taken from each participant. | Procedure: Blood sample<br>* 20 ml blood sample taken from vein in arm<br>|
| Other: High Risk<br>150 High Risk going onto invasive diagnostic procedure. The only intervention is a 20 ml blood sample will be taken from each participant. | Procedure: Blood sample<br>* 20 ml blood sample taken from vein in arm<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of IONA test results which are concordant or discordant with Invasive test or Birth outcome. | IONA test results will be compared to Karyotyping from birth outcome and invasive procedures. | 18 months |
Evaluation of the Occurrence of Acute Complications Caused by a Central Venous Catheter Placement

Study Overview
=================
Brief Summary
-----------------
It is an observational, prospective, monocentric study. The purpose of the study is to assess the acute complications rate caused by a central venous catheter placement. All the patients who require a central venous placement could be enrolled in the study. The study will not change the usual practice. The placement will be on day 1 and patients will be contacted by phone on day 7 to identify potential complications and to assess pain. Anaesthesia staff will keep patients under surveillance to control the absence of late complications.

Official Title
-----------------
Evaluation of the Occurrence of Acute Complications Caused by a Central Venous Catheter Placement: Observational, Prospective, Monocentric Study

Conditions
-----------------
Anesthesia

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age >= 18. Patient who requires the placement of a central venous catheter (a portacath (PAC), a peripherally inserted central catheter (PICC) or a tunnelled catheter). Patient able to understand, read and write French. Mandatory affiliation with a health insurance system. Exclusion Criteria: Active infection at placement of the central venous catheter. Patient who can't be contacted by phone. Patient who is likely to have a femoral venous catheter placement.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Central venous catheter<br>All patients who require the placement of a central venous catheter | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Estimate the acute complications rate | Placement of the central venous catheter on day 1 and follow-up of potential acute complications | From day 1 to day 7 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Assess the preoperative anxiety | By means of Beck anxiety inventory | On day 1 | 
| Assess patients satisfaction about the catheter | By means of a questionnary filled in by patients at home | On day 7 | 
| Assess postoperative pain | The pain will be assessed on day 1 by a visual analogic scale and on day 7 by a verbal numeric scale | On day 1 and on day 7 | 
| Assess the rate of late complications | The anaesthesia staff will keep patients under surveillance for potential late complications. | Up to 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Catheterization, Central Venous